MIRA-1 is a maleimide analogue that induces apoptosis in mutant p53 cells by restoring p53-dependent transcriptional activation. MIRA-1 inhibits the growth of Saos-2-His273 cells expressing mutant p53, and possesses anticancer activity. At a concentration of 5 μM for 14 days, MIRA-1 significantly reduced the number of colonies formed by His273-expressing Saos-2 cells, but was much less effective in inhibiting p53-deficient Saos-2 cells. MIRA-1 induced EGFP expression, MDM2 and Bax in SKOV-His175 cells at concentrations of 5 and 10 μM for 24 hours[1].
MIRA-1 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Normal PBMCs
0.2, 2, 20 μM
72 hours
Normal PBMCs were less sensitive to NSC 19630, with an IC50 of 9.28 ± 0.23 μM.
J Hematol Oncol. 2016 Nov 9;9(1):121
C91PL cells
0.2, 2, 20 μM
72 hours
NSC 19630 induced apoptosis in a dose-dependent manner, with an IC50 of 2.76 ± 0.29 μM.
J Hematol Oncol. 2016 Nov 9;9(1):121
ATL-derived cell lines (ED)
3 μM
48 hours
NSC 19630 treatment showed significant accumulation of cells in the S-phase when compared with DMSO-exposed cells, suggesting that exposure to the helicase inhibitor induced accumulation of cells in the S-phase in ATL-derived cell lines.
NSC 19630 treatment showed significant accumulation of cells in the S-phase when compared with DMSO-exposed cells, suggesting that exposure to the helicase inhibitor induced accumulation of cells in the S-phase in HTLV-1-transformed and ATL-derived cell lines.
搜索
